These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26397936)

  • 21. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
    Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
    Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
    Halaas JL; Moskowitz CH; Horwitz S; Portlock C; Noy A; Straus D; O'Connor OA; Yahalom J; Zelenetz AD
    Leuk Lymphoma; 2005 Apr; 46(4):541-7. PubMed ID: 16019482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hope for very elderly patients with diffuse large B-cell lymphoma.
    Ribera JM
    Lancet Oncol; 2011 May; 12(5):412-3. PubMed ID: 21482185
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma.
    Lakshmaiah KC; Asati V; Babu K G; D L; Jacob LA; M C SB; K N L; L K R; A H R; Saldanha S; Koppaka D; Patidar R; C S P
    Eur J Haematol; 2018 Jun; 100(6):644-648. PubMed ID: 29569279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
    Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
    Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
    Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
    Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma.
    Kassam S; Bower M; Lee SM; de Vos J; Fields P; Gandhi S; Nelson M; Montoto S; Tenant-Flowers M; Burns F; Marcus R; Edwards SG; Cwynarski K
    Leuk Lymphoma; 2013 Sep; 54(9):1921-7. PubMed ID: 23206228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma.
    Camus V; Tilly H
    Expert Rev Hematol; 2017 Dec; 10(12):1047-1055. PubMed ID: 27791447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
    Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
    [No Abstract]   [Full Text] [Related]  

  • 32. The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
    Tomita N; Suzuki T; Miyashita K; Yamamoto W; Motohashi K; Tachibana T; Takasaki H; Kawasaki R; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Taguchi J; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Motomura S; Kawamoto K; Sone H; Takizawa J
    Leuk Lymphoma; 2016 Dec; 57(12):2763-2770. PubMed ID: 27320054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.
    Stefoni V; Casadei B; Bottelli C; Gaidano G; Ciochetto C; Cabras MG; Ansuinelli M; Argnani L; Broccoli A; Gandolfi L; Pellegrini C; Zinzani PL
    Blood Cancer J; 2016 May; 6(5):e425. PubMed ID: 27176801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
    Herbrecht R; Cernohous P; Engert A; Le Gouill S; Macdonald D; Machida C; Myint H; Saleh A; Singer J; Wilhelm M; van der Jagt R
    Ann Oncol; 2013 Oct; 24(10):2618-2623. PubMed ID: 23946328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
    Hosoi M; Yamamoto G; Imai Y; Kurokawa M
    Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
    [No Abstract]   [Full Text] [Related]  

  • 36. The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Leuk Lymphoma; 2017 Mar; 58(3):736-739. PubMed ID: 27686739
    [No Abstract]   [Full Text] [Related]  

  • 37. [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma].
    Nakashima T; Kiba T; Ogawa Y; Kimura A; Kido M; Okikawa Y; Ito T; Saito A; Hosokawa A; Shintani H; Okada Y; Taniguchi T; Taniyama K; Kozawa K; Niimi H
    Gan To Kagaku Ryoho; 2012 May; 39(5):809-12. PubMed ID: 22584337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
    Hainsworth JD; Arrowsmith ER; McCleod M; Hsi ED; Hamid O; Shi P; Lin BK; Fayad LE
    Leuk Lymphoma; 2016; 57(1):216-8. PubMed ID: 25956042
    [No Abstract]   [Full Text] [Related]  

  • 39. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.